Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future

Rey-Cárdenas, M.; Guerrero-Ramos, Félix; Lista, Alfonso Gómez De Liaño; Carretero-González, Alberto; Bote, H.; Herrera-Juárez, Mercedes; Carril-Ajuria, Lucía; Martín-Soberón, María Cruz; Sepúlveda, Juan Manuel; Billalabeitia, E. González; Castellano, Daniel; Velasco, Guillermo

doi:10.1016/j.ctrv.2020.102142

Cited by 36 publications

(35 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most promising finding was that in BLCA, diverse immune cell surface marker and immune infiltration levels are associated with MT1L expression. Recently, ICT has changed the intervention measures for urinary cancer (including advanced bladder cancer) [31,32]. ICT has achieved an excellent curative effect in BLCA; however, it is undeniable that only some BLCA patients can benefit from ICT.…”

Section: Discussionmentioning

confidence: 99%

Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA

et al. 2021

View full text Add to dashboard Cite

Background BLCA is a common cancer worldwide, and it is both aggressive and fatal. Immunotherapy (ICT) has achieved an excellent curative effect in BLCA; however, only some BLCA patients can benefit from ICT. MT1L is a pseudogene, and a previous study suggested that MT1L can be used as an indicator of prognosis in colorectal cancer. However, the role of MT1L in BLCA has not yet been determined. Methods Data were collected from TCGA, and logistic regression, Kaplan-Meier plotter, and multivariate Cox analysis were performed to demonstrate the correlation between the pseudogene MT1L and the prognosis of BLCA. To identify the association of MT1L with tumor-infiltrating immune cells, TIMER and TISIDB were utilized. Additionally, GSEA was performed to elucidate the potential biological function. Results The expression of MT1L was decreased in BLCA. Additionally, MT1L was positively correlated with immune cells, such as Tregs (ρ = 0.708) and MDSCs (ρ = 0.664). We also confirmed that MT1L is related to typical markers of immune cells, such as PD-1 and CTLA-4. In addition, a high MT1L expression level was associated with the advanced T and N and high grade in BLCA. Increased expression of MT1L was significantly associated with shorter OS times of BLCA patients (p < 0.05). Multivariate Cox analysis revealed that MT1L expression could be an independent prognostic factor in BLCA. Conclusion Collectively, our findings demonstrated that the pseudogene MT1L regulates the immune microenvironment, correlates with poor survival, and is an independent prognostic biomarker in BLCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA

et al. 2021

View full text Add to dashboard Cite

show abstract

“…BLASST-1 assessed the efficiency of neoadjuvant combination of immunotherapy and chemotherapy. The pCR rate of patients receiving neoadjuvant nivolumab, gemcitabine, and cisplatin was reported as 49% ( 47 ). The emerging results from several clinical trials exploring the role of neoadjuvant immunotherapy are promising; however, further long-term survival data are needed to demonstrate the survival benefit of neoadjuvant immunotherapy.…”

Section: Neoadjuvant Cisplatin-based Chemotherapy In Muscle-invasive ...mentioning

confidence: 99%

Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature

Xie

Cao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Muscle-invasive bladder cancer (MIBC) is an aggressive disease requiring active management. Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is considered the standard treatment paradigm for MIBC patients, which could result in significant perioperative mortality and morbidity, as well as the significant alteration of the quality of life (QOL). Notably, multimodal bladder-preserving treatment strategies have been recommended for highly selected patients. Pathologic complete response (pCR) after NAC is a powerful prognostic indicator of survival for patients with MIBC. Clinical complete response (cCR) is then introduced as a complementary endpoint for pCR to assess disease status preoperatively. Bladder preservation strategy for patients who achieve cCR following NAC is emerging as a new treatment concept. However, the efficiency of the conservative strategy remains controversial. In this state-of-the-art review, we discuss the advantages and limitations of cCR and the feasibility and safety of bladder preservation strategy in highly selected MIBC patients who achieve cCR following NAC. We conclude that a conservative strategy can be considered a reasonable alternative to RC in carefully selected cCR MIBC patients, leading to acceptable oncological outcomes.

show abstract

“…Common treatment strategies for MIBC include radical cystectomy, neoadjuvant therapy, the use of immune checkpoint inhibitors (ICIs), perioperative radiotherapy, and chemotherapy 1 . Although the prognosis of patients with BLCA has improved with these treatments, recent studies have shown that the use of ICIs can further improve patient outcomes and disease-free survival 7 , 8 .…”

Section: Introductionmentioning

confidence: 99%

Identification of a novel immune-related long noncoding RNA signature to predict the prognosis of bladder cancer

Ren

Zuo

Yang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Tumour immune regulation has attracted widespread attention, and long noncoding RNAs (lncRNAs) play an important role in this process. Therefore, we evaluated patient prognosis by exploring the relationship between bladder cancer (BLCA) and immune-related lncRNAs (IRlncRNAs). Transcriptome data and immune-related genes were analysed for coexpression, and then, the IRlncRNAs were analysed to determine the differentially expressed IRlncRNAs (DEIRlncRNAs) between normal and tumour samples in The Cancer Genome Atlas. The screened lncRNAs were pairwise paired and combined with clinical data, and finally, a signature was constructed by Lasso regression and Cox regression in 13 pairs of DEIRlncRNAs. According to the Akaike information criterion (AIC) values of the 1-year receiver operating characteristic curve, BLCA patients were stratified into high- or low-risk groups. The high-risk group had a worse prognosis. A comprehensive analysis showed that differences in risk scores were associated with the immune status of BLCA-infiltrated patients. The identified signature was correlated with the expression of immune checkpoint inhibitor-related molecules and sensitivity to chemotherapeutic drugs. We also identified three BLCA clusters with different immune statuses and prognoses that are also associated with immunotherapy response and drug sensitivity. In conclusion, we constructed a powerful predictive signature with high accuracy and validated its prognostic value.

show abstract

Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future

Cited by 36 publications

References 56 publications

Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA

Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA

Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature

Identification of a novel immune-related long noncoding RNA signature to predict the prognosis of bladder cancer

Contact Info

Product

Resources

About